Diagnostic potential of circulating cell-free nuclear and mitochondrial DNA for several cancer types and nonmalignant diseases: A study on suspected cancer patients

被引:6
|
作者
Sundquist, Kristina [1 ]
Sundquist, Jan [1 ]
Hedelius, Anna [1 ]
Memon, Ashfaque A. [1 ]
机构
[1] Lund Univ, Ctr Primary Hlth Care Res, Malmo, Sweden
关键词
biomarker; cancer; circulating DNA; diagnostic; mitochondrial DNA; nuclear DNA; PLASMA; ORIGIN;
D O I
10.1002/mc.23261
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Circulating cell-free nuclear DNA (nDNA) has been implicated in individual cancer types with a diagnostic value; however, the role of cell-free mitochondrial DNA (mtDNA) in cancers is controversial. We aimed to investigate and compare the diagnostic potential of both nDNA and mtDNA for multiple cancers and to investigate their ability to distinguish multiple cancers from healthy controls and from nonmalignant diseases. We also investigated the prognostic value of both nDNA and mtDNA. The absolute copy number of circulating DNAs in suspected cancer patients (n = 286) referred to a cancer diagnostic center and healthy controls (n = 109) was quantified by droplet digital polymerase chain reaction. Among the suspected cancer patients, 66 (23%) were diagnosed with various cancers, 193 (67%) with nonmalignant diseases, and 27 (10%) with no active disease. Levels of nDNA were significantly higher in cancers (copies/mu l; mean +/- SD, 21.0 +/- 14.2) as compared with nonmalignant diseases (15.2 +/- 10.0) and controls (9.3 +/- 4.1). In contrast, levels of mtDNA were significantly lower in cancers (copies/mu l; mean +/- SD, 68,557 +/- 66,663) and nonmalignant diseases (60,174 +/- 55,831) as compared with controls (98,714 +/- 77,789). Receiver operating curve analysis showed that nDNA not only could distinguish multiple cancers from controls (area under curve [AUC] = 0.78; 95% confidence interval [CI] = 0.70-0.86) but also from nonmalignant diseases (AUC = 0.68; 95% CI = 0.59-0.76). However, mtDNA could only differentiate cancers from controls (AUC = 0.65; 95% CI = 0.56-0.73). Higher levels of nDNA were also associated with increased mortality in the cancer patients (hazard ratio = 2.3; 95% CI = 1.1-4.7). Circulating cell-free nDNA, but not the mtDNA, could distinguish multiple cancers from nonmalignant diseases and was associated with poor survival of cancer patients.
引用
收藏
页码:1362 / 1370
页数:9
相关论文
共 50 条
  • [31] NGS-based accurate and efficient detection of circulating cell-free mitochondrial DNA in cancer patients
    Liu, Yang
    Zhou, Kaixiang
    Guo, Shanshan
    Wang, Yang
    Ji, Xiaoying
    Yuan, Qing
    Su, Liping
    Guo, Xu
    Gu, Xiwen
    Xing, Jinliang
    MOLECULAR THERAPY-NUCLEIC ACIDS, 2021, 23 : 657 - 666
  • [32] Sequencing Circulating Cell-Free DNA: The Potential to Refine Precision Cancer Medicine
    Tie, Jeanne
    Gibbs, Peter
    CLINICAL CHEMISTRY, 2016, 62 (06) : 796 - 798
  • [33] Evaluating the prognostic potential of circulating cell-free DNA in advanced thyroid cancer
    Wijewardene, Ayanthi
    Clifton-Bligh, Roderick J.
    Wang, Bin
    Luxford, Catherine
    Robinson, Bruce G.
    Bullock, Martyn
    Gild, Matti
    ENDOCRINE-RELATED CANCER, 2025, 32 (02)
  • [34] CIRCULATING HPV CELL-FREE DNA IN CERVICAL CANCER
    Mittelstadt, Suzana
    Schroeder, Christopher
    Kelemen, Olga
    Engler, Tobias
    Admard, Jakob
    Gschwind, Axel
    Koch, Andre
    Woerz, Sarah Elisabeth
    Oberlechner, Ernst
    Hoffmann, Sascha
    Andress, Juergen
    Neis, Felix
    Kraemer, Bernhard
    Bonzheim, Irina
    Staebler, Annette
    Stubenrauch, Frank
    Iftner, Thomas
    Ossowski, Stephan
    Kommoss, Stefan
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2022, 32 : A40 - A40
  • [35] Methylation of cell-free circulating DNA in the diagnosis of cancer
    Warton, Kristina
    Samimi, Goli
    FRONTIERS IN MOLECULAR BIOSCIENCES, 2015, 2
  • [36] Bioinformatics Analysis for Circulating Cell-Free DNA in Cancer
    Huang, Chiang-Ching
    Du, Meijun
    Wang, Liang
    CANCERS, 2019, 11 (06):
  • [37] CIRCULATING CELL-FREE DNA IN ENDOMETRIAL CANCER.
    Cicchillitti, L.
    Corrado, G.
    De Angeli, M.
    Mancini, E.
    Baiocco, E.
    Chiofalo, B.
    Patrizi, L.
    Zampa, A.
    Piaggio, G.
    Vizza, E.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2017, 27 : 1066 - 1066
  • [38] CIRCULATING HPV CELL-FREE DNA IN CERVICAL CANCER
    Mittelstadt, Suzana
    Schroeder, Christopher
    Kelemen, Olga
    Jakob, Admard
    Gschwind, Axel
    Koch, Andre
    Woerz, Sarah
    Oberlechner, Ernst
    Hoffmann, Sascha
    Engler, Tobias
    Andress, Jurgen
    Neis, Felix
    Kramer, Bernhard
    Bonzheim, Irina
    Staebler, Annette
    Stubenrauch, Frank
    Ossowski, Stephan
    Kommoss, Stefan
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2022, 32 : A20 - A20
  • [39] Circulating cell-free DNA for cancer early detection
    Gao, Qiang
    Zeng, Qiang
    Wang, Zhijie
    Li, Chengcheng
    Xu, Yu
    Cui, Peng
    Zhu, Xin
    Lu, Huafei
    Wang, Guoqiang
    Cai, Shangli
    Wang, Jie
    Fan, Jia
    INNOVATION, 2022, 3 (04):
  • [40] Circulating Cell-Free Tumour DNA in the Management of Cancer
    Francis, Glenn
    Stein, Sandra
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2015, 16 (06) : 14122 - 14142